Bafna Pharmaceuticals Share Price
16 Nov, 2026 3:15 PM (IST)
Bafna Pharmaceuticals Performance
- Today's Low
- ₹473
- Today's High
- ₹492
- 52 Week Low
- ₹95
- 52 Week High
- ₹502
- Open Price₹492
- Previous Close₹482
- Volume30,331
- 50 DMA₹403.90
- 100 DMA₹339.60
- 200 DMA₹267.20
Bafna Pharmaceuticals Chart
Investment Returns
- Over 1 Month + 4.57%
- Over 3 Month + 83.55%
- Over 6 Month + 249.59%
- Over 1 Year + 161.08%
Smart Investing Starts Here Start SIP with Bafna Pharmaceuticals for Steady Growth!
Bafna Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 97.2
- PEG Ratio
- 3.1
- Market Cap Cr
- 1,119
- P/B Ratio
- 11.6
- Average True Range
- 10.3
- EPS
- 4.9
- Dividend Yield
- 0
- MACD Signal
- 21.8
- RSI
- 63.92
- MFI
- 29.62
Latest Stock News Updates
We herewith enclose the Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter & Half Year ended September 30, 2026 as published in ''Business Standard'' and ''Makkal Kural'' on November 13, 2026.
- BSE India
- 19 hours 37 minutes ago
<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Bafna Pharmaceuticals announced Q2FY27 results</strong></span></h3> <p><strong>Financial Highlights:</strong><!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--><br /> <em data-complete="true" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="LFsGHb#ycPkjf" jsuid="FIQqZc_1k"><!--TgQPHd|||[]--></em><!--TgQPHd|||[]--></p> <ul data-complete="true" data-hveid="CAAICRAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="FIQqZc_1r"> <li data-complete="true" data-hveid="CAAICRAB" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="FIQqZc_1s"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="FIQqZc_1u">Revenue from operations:<!--TgQPHd|||[]--></strong> Revenue from operations stood at Rs 4,766.56 lakh in Q2FY27, reflecting an increase of 79.31% QoQ from Rs 2,658.32 lakh in Q1FY27 and 34.39% YoY from Rs 3,546.82 lakh in Q2FY26. For H1FY27, revenue from operations grew 5.93% YoY to Rs 7,424.88 lakh compared to Rs 7,009.22 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICRAE" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="FIQqZc_21"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="FIQqZc_23">Total income:<!--TgQPHd|||[]--></strong> Total income reached Rs 4,879.97 lakh in Q2FY27, marking a rise of 71.26% QoQ over Rs 2,849.42 lakh in Q1FY27 and 33.16% YoY over Rs 3,664.79 lakh in Q2FY26. In H1FY27, total income increased 7.55% YoY to Rs 7,729.39 lakh from Rs 7,186.75 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICRAH" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="FIQqZc_2a"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="FIQqZc_2c">Profit before tax (PBT):<!--TgQPHd|||[]--></strong> Profit before tax was Rs 684.82 lakh in Q2FY27, surging 9,018.77% QoQ from Rs 7.51 lakh in Q1FY27 and rising 119.15% YoY from Rs 312.49 lakh in Q2FY26. For H1FY27, profit before tax increased 6.29% YoY to Rs 692.33 lakh against Rs 651.38 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICRAK" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="FIQqZc_2j"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="FIQqZc_2l">Profit after tax (PAT):<!--TgQPHd|||[]--></strong> Profit for the period stood at Rs 684.82 lakh in Q2FY27, up 9,018.77% QoQ compared to Rs 7.51 lakh in Q1FY27 and up 119.15% YoY compared to Rs 312.49 lakh in Q2FY26. During H1FY27, profit for the period grew 6.29% YoY to Rs 692.33 lakh from Rs 651.38 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICRAN" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="FIQqZc_2s"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="FIQqZc_2u">Earnings per share (EPS):<!--TgQPHd|||[]--></strong> Basic and diluted EPS was Rs 2.89 in Q2FY27, rising 9,533.33% QoQ from Rs 0.03 in Q1FY27 and 118.94% YoY from Rs 1.32 in Q2FY26. For H1FY27, basic and diluted EPS rose 6.55% YoY to Rs 2.93 compared to Rs 2.75 in H1FY26.<!--TgQPHd|||[]--></li> </ul> <p><a class="lb" href="/get-document/post/pdf/5943692/" target="_blank">Result PDF</a></p>
- Trendlyne
- 5 days 13 hours ago
We herewith enclose the Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026 as approved by the Board of Directors in its Meeting held on November 11, 2026.
- BSE India
- 5 days 13 hours ago
Bafna Pharmaceuticals Financials
Bafna Pharmaceuticals Technicals
EMA & SMA
- Bearish Moving Average 2
- Bullish Moving Average 14
- 20 Day
- ₹453.60
- 50 Day
- ₹403.90
- 100 Day
- ₹339.60
- 200 Day
- ₹267.20
Resistance and Support
- R3 503.90
- R2 497.70
- R1 485.40
- S1 466.80
- S2 460.60
- S3 448.30
Bafna Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-11-11 | Quarterly Results | |
| 2026-08-11 | Quarterly Results | |
| 2026-05-29 | Audited Results | |
| 2026-02-11 | Quarterly Results | |
| 2025-11-11 | Quarterly Results |
About Bafna Pharmaceuticals
Bafna Pharmaceuticals is engaged in the business of manufacturing of finished pharmaceutical formulations. View More- NSE Symbol
- BAFNAPH
- BSE Symbol
- 532989
- ISIN
- INE878I01022
Similar Stocks to Bafna Pharmaceuticals
Popular Stocks
Bafna Pharmaceuticals FAQs
Bafna Pharmaceuticals share price is ₹473 As on 17 November, 2026 | 06:45
The Market Cap of Bafna Pharmaceuticals is ₹1118.9 Cr As on 17 November, 2026 | 06:45
The P/E ratio of Bafna Pharmaceuticals is 97.2 As on 17 November, 2026 | 06:45
The PB ratio of Bafna Pharmaceuticals is 11.6 As on 17 November, 2026 | 06:45
The 52 week High & Low of Bafna Pharmaceuticals is ₹501.6/₹94.8 respectively As on 17 November, 2026 | 06:45
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.